Navigation Links
Biomedical research center opens in Liverpool
Date:2/10/2009

Scientists at the University of Liverpool will launch a new national research centre to further understanding into infections such as HIV and tuberculosis.

The Centre, which will be opened by Sir William Stewart, Chairman of the Health Protection Agency, is one of 12 in the country to be funded by the National institute for Health Research (NIHR) as part of the Government's health research strategy. The joint venture has received 13.5 million funding from NIHR and a further 6.4million from the North West Development Agency. It will be run jointly by the University, the Royal Liverpool and Broadgreen University Hospitals Trust and the Liverpool School of Tropical Medicine.

The Centre will focus on four areas hospital and community acquired infections, chest infections, sexual health, and safety of antimicrobial drugs. Researchers will also have access to state-of-the-art facilities such as a new clinical research unit to trial new drug treatments and a medical microbiology facility for the identification and safe handling of bacteria.

Sir William said: "This is important work that will take place in first-rate facilities. I believe this Centre will be a magnet for our very best scientists, retaining and attracting the best brains to Liverpool and the North West, not just from elsewhere in the UK, but internationally. It is a privilege and pleasure to open such an important and worthwhile development."

Professor Peter Winstanley, Executive Director of the Biomedical Research Centre (BRC), said: "This prestigious new centre puts Liverpool at the cutting edge of research and means we can pioneer new drugs and diagnostic tools for a range of conditions. We will be investigating ways of alleviating suffering and treating infections which affect millions of people around the world."

The Centre will deliver 13 projects over the next five years, which include areas such as genetic testing to identify who is most likely to be allergic to penicillin, and vaccine development for pneumonia a major cause of death in children and adults worldwide. Research will also include identification of the factors that cause HIV patients to develop resistance to drug therapies.

Tony Bell, Royal Liverpool and Broadgreen University Hospitals Trust Chief Executive, said: "There has been groundbreaking medical research going on in Liverpool for many years.

The new Biomedical Research Centre acknowledges the excellence of that work and gives us the opportunity to make a much bigger impact on the treatment of infections worldwide. I am delighted to be part of such a vital development."

The opening of the Biomedical Research Centre will take place on Tuesday, 10 February at 11.00am in the Education Centre at the Royal Liverpool and Broadgreen University Hospital Trust.


'/>"/>

Contact: Samantha Martin
samantha.martin@liv.ac.uk
01-517-942-248
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Dr. Huda Zoghbi to receive 2009 Vilcek Prize in biomedical research
2. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
3. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
4. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
5. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
6. Response Biomedical Corporation Announces Change of Executives
7. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
8. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
9. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 02, 2016 , ... Metabolic Code (MC) ... nutraceuticals and help doctors more efficiently manage their practice. Power2Practice is adding ... platform for Integrative and Functional Medicine. , The Metabolic Code platform provides ...
(Date:12/4/2016)... ... , ... While James Earl Jones is known for myriad roles on stage ... "Front Page". One of the forthcoming episodes examines mammogram techniques; a very important part ... part due to early detection. Like any other disease, treatments have a much higher ...
(Date:12/4/2016)... California (PRWEB) , ... December 04, 2016 , ... ... third presets that have new attractive animation styles with unique displacement design elements," ... features 30 pre-animated lower third designs. Choose from a variety of design styles ...
(Date:12/4/2016)... ... , ... Responsible dental care hinges on regular brushing of the teeth. However, ... important necessity inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. ... or avoid bad techniques of brushing the teeth in order to prevent cavities," he ...
(Date:12/2/2016)... ... December 02, 2016 , ... Two years ... heroin that was watched live by 1 million viewers and won numerous honors, ... , ASU students at the Walter Cronkite School of Journalism and Mass Communication ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: